市場調査レポート

商品コード

1798030

自己免疫性皮膚疾患治療市場の2032年までの予測：疾患タイプ別、治療タイプ別、投与経路別、エンドユーザー別、地域別の世界分析

Autoimmune Skin Diseases Treatment Market Forecasts to 2032 - Global Analysis By Disease Type, Therapy Type, Route of Administration, End User and By Geography

出版日: 2025年08月07日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 613,868円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 776,580円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 939,292円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,109,400円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.92円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の自己免疫性皮膚疾患治療市場は2025年に100億5,000万米ドルを占め、予測期間中にCAGR 14.4％で成長し、2032年には257億7,000万米ドルに達する見込みです。

皮膚の自己免疫疾患「治療」という用語は、免疫系が不注意に健康な皮膚細胞を標的にすることによって引き起こされる皮膚疾患を治療するために使用される医療処置を表します。乾癬、白斑、エリテマトーデス、強皮症、天疱瘡、疱疹状皮膚炎などはこれらの疾患の一部です。治療の主要目標は、皮膚の損傷を最小限に抑え、炎症を抑え、異常な免疫反応を抑制し、症状を緩和し、再燃を避けることです。全身と局所コルチコステロイド、免疫抑制剤、生物製剤、光線療法、支持的スキンケアなどが一般的な治療法です。生活の質の向上、合併症の減少、病気の進行の遅延は、すべて早期診断と個々の患者に合った治療戦略にかかっています。

自己免疫性皮膚疾患の有病率の上昇

スクリーニングの改善と認知度の向上により、白斑、狼瘡、乾癬などの疾患の診断が増加しています。ヘルスケア専門家は、このような患者基盤の拡大を受けて、標的治療、免疫調整剤、先進的生物製剤を採用しています。こうした患者のアンメットニーズを満たすため、製薬会社は研究開発費を増やしています。また、有利なヘルスケア規制や皮膚科医療へのアクセス改善により、治療導入率も上昇しています。自己免疫性皮膚疾患の有病率の増加は、市場の着実な拡大を後押ししています。

生物製剤や先進治療の高額な費用

多くの患者がこれらの医薬品の代金を支払うことができないため、医薬品へのアクセスやアドヒアランスが制限されます。また、高額な費用は保険会社やヘルスケアシステムに負担をかける。その結果、保険適用が制限され、償還が困難になります。その結果、患者はより効果の低い選択肢を選ぶことになるかもしれません。こうした金銭的な障害が最先端治療の普及を妨げ、市場の成長を制限しています。

ヘルスケア支出と診断の成長

最先端の生物製剤や重点的な治療法の使用を促す助成金の増加により、患者の転帰は改善されます。診断能力の進歩により、より正確な疾病分類と早期発見が可能になります。早期かつ正確な診断によるタイムリーな介入は、疾患の進行や合併症を遅らせる。都市部でも農村部でも治療へのアクセスが向上することは、ヘルスケアインフラの発展によって可能となります。これらの要素が相まって、自己免疫性皮膚疾患の治療に対する需要が増加し、市場が成長するのです。

安全性への懸念と副作用

感染症や臓器障害のような重篤な副作用の危険性は、多くの治療に存在します。このような健康被害により、患者は治療を避けたり、中止したりすることがあります。さらに、安全性プロファイルが弱い場合、医師は特定の薬剤を薦めたがらないこともあります。その結果、患者のコンプライアンスと市場受容性は低下します。したがって、有益な医薬品の採用は、危険への恐れによって遅々として進まないのです。

COVID-19の影響

COVID-19の大流行は、サプライチェーンを混乱させ、臨床検査を遅らせ、医療施設への患者のアクセスを制限することによって、自己免疫性皮膚疾患治療市場に大きな影響を与えました。閉鎖とヘルスケア資源の再配分により、診断と治療スケジュールが延期され、患者の転帰に影響を与えました。遠隔医療の導入が加速し、遠隔診察や配合管理が可能になりました。製薬会社は生産と流通における課題に直面したが、同時に先進的な治療法の開発への注目も高まりました。パンデミック後の回復は、選択的治療の再開、ヘルスケアへのアクセスの改善、自己免疫性皮膚疾患の管理に対する意識の高まりによってもたらされます。

予測期間中、生物製剤セグメントが最大となる見込み

生物製剤セグメントは、根本的な免疫機能障害に対処する標的療法を提供することで、予測期間中に最大の市場シェアを占めると予想されます。これらの治療は、従来型薬剤と比較して高い有効性と長い寛解期間を提供し、患者の需要を後押しします。生物製剤と送達方法の進歩は安全性と利便性を高め、採用率を高めています。乾癬やアトピー性皮膚炎などの疾患に対する新規生物製剤の承認が増加し、治療ポートフォリオが拡大しています。ヘルスケアプロバイダや患者の意識の高まりは、生物製剤の市場成長をさらに加速させています。

予測期間中にCAGRが最も高くなると予測されるのは在宅ケアセグメントです。

予測期間中、在宅ケアセグメントは、患者が自宅で治療やモニタリングに便利にアクセスできるため、頻繁な通院の必要性が減少し、最も高い成長率を示すと予測されます。また、自己投与オプションやヘルスケアプロバイダからの遠隔指導により、より良い治療アドヒアランスをサポートします。携帯機器と遠隔医療の進歩は、在宅ケアの実現性を高めています。全体として、在宅ケアは患者の転帰を改善すると同時にヘルスケアコストを削減し、市場成長を牽引しています。

最大のシェアを占める地域

予測期間中、北米の地域が最大の市場シェアを占めると予想されるが、これは高い疾患罹患率、整備された医療インフラ、旺盛な研究開発資金が背景にあります。特に生物製剤やJAK阻害剤を中心とする先進的な医薬品と有利な償還施策が、新規治療法の急速な普及を支えています。規制当局が医薬品承認の迅速化とバイオ類似品への参入を促進しています。AIによる画像診断やマルチプレックスアッセイなど、最先端の診断技術や精密医療技術の利用が増加しており、バイオテクノロジー企業と学術機関との戦略的提携により、乾癬、湿疹、ループスなどの疾患に対する治療法の継続的なイノベーションが促進されています。

CAGRが最も高い地域

予測期間中、アジア太平洋が最も高いCAGRを示すと予測されます。これは、高齢化、都市化、ライフスタイルの進化に伴う自己免疫疾患罹患率の上昇が背景にあります。ヘルスケアインフラへの投資、公的保険の適用拡大、ジェネリック医薬品の生産が治療へのアクセスを強化します。新興技術としては、AIを活用した遠隔皮膚科学、モバイル診断、ハイパースペクトルイメージング、開発中のナノ構造局所治療などがあります。世界のイノベーション動向は、地域のニーズや医療格差に合わせた診断薬や精密治療のスケーラブルな展開を支援する世界製薬企業との連携別、費用対効果の高い地域特化型のソリューションを重視しています。

無料カスタマイズサービス

本レポートをご購読の顧客は、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

企業プロファイル
- 追加市場参入企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携による主要企業のベンチマーキング

イントロダクション
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東・アフリカ

第10章主要開発

契約、パートナーシップ、コラボレーション、ジョイントベンチャー
買収と合併
新製品発売
事業拡大
その他の主要戦略

第11章企業プロファイリング

AbbVie Inc.
Amgen Inc.
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Novartis AG
Pfizer Inc.
Bristol Myers Squibb Company
Biogen Inc.
Sanofi S.A.
UCB S.A.
GlaxoSmithKline plc
Regeneron Pharmaceuticals, Inc.
AstraZeneca plc
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
Roche Holding AG
Horizon Therapeutics plc
Incyte Corporation

図表

List of Tables

Table 1 Global Autoimmune Skin Diseases Treatment Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
Table 3 Global Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
Table 4 Global Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
Table 5 Global Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
Table 6 Global Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
Table 7 Global Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
Table 8 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
Table 9 Global Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
Table 10 Global Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
Table 11 Global Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 12 Global Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 13 Global Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
Table 14 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
Table 15 Global Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 16 Global Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
Table 17 Global Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
Table 18 Global Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
Table 19 Global Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
Table 20 Global Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
Table 21 Global Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 22 Global Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 23 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
Table 24 North America Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 25 North America Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
Table 26 North America Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
Table 27 North America Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
Table 28 North America Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
Table 29 North America Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
Table 30 North America Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
Table 31 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
Table 32 North America Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
Table 33 North America Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
Table 34 North America Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 35 North America Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 36 North America Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
Table 37 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
Table 38 North America Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 39 North America Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
Table 40 North America Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
Table 41 North America Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
Table 42 North America Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
Table 43 North America Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
Table 44 North America Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 45 North America Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 46 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
Table 47 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 48 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
Table 49 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
Table 50 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
Table 51 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
Table 52 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
Table 53 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
Table 54 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
Table 55 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
Table 56 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
Table 57 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 58 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 59 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
Table 60 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
Table 61 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 62 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
Table 63 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
Table 64 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
Table 65 Europe Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
Table 66 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
Table 67 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 68 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 69 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
Table 70 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 71 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
Table 72 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
Table 73 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
Table 74 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
Table 75 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
Table 76 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
Table 77 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
Table 78 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
Table 79 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
Table 80 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 81 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 82 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
Table 83 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
Table 84 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 85 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
Table 86 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
Table 87 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
Table 88 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
Table 89 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
Table 90 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 91 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 92 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
Table 93 South America Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 94 South America Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
Table 95 South America Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
Table 96 South America Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
Table 97 South America Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
Table 98 South America Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
Table 99 South America Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
Table 100 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
Table 101 South America Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
Table 102 South America Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
Table 103 South America Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 104 South America Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 105 South America Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
Table 106 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
Table 107 South America Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 108 South America Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
Table 109 South America Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
Table 110 South America Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
Table 111 South America Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
Table 112 South America Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
Table 113 South America Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 114 South America Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 115 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
Table 116 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 117 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
Table 118 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
Table 119 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
Table 120 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
Table 121 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
Table 122 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
Table 123 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
Table 124 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
Table 125 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
Table 126 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 127 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 128 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
Table 129 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
Table 130 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 131 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
Table 132 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
Table 133 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
Table 134 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
Table 135 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
Table 136 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 137 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 138 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Product Code: SMRC30400

According to Stratistics MRC, the Global Autoimmune Skin Diseases Treatment Market is accounted for $10.05 billion in 2025 and is expected to reach $25.77 billion by 2032 growing at a CAGR of 14.4% during the forecast period. Autoimmune Conditions of the Skin the term "treatment" describes the medical procedures used to treat skin conditions brought on by the immune system inadvertently targeting healthy skin cells. Psoriasis, vitiligo, lupus erythematosus, scleroderma, pemphigus, and dermatitis herpetiformis are some of these ailments. The main goals of treatment are to minimise skin damage, reduce inflammation, inhibit aberrant immune responses, relieve symptoms, and avoid flare-ups. Systemic and topical corticosteroids, immune-suppressants, biologic treatments, phototherapy, and supportive skincare are common methods. Improving quality of life, decreasing complications, and delaying the progression of disease all depend on early diagnosis and individualized treatment strategies.

Market Dynamics:

Driver:

Rising prevalence of autoimmune skin conditions

Improved screening and more awareness have led to a rise in the diagnosis of conditions like vitiligo, lupus, and psoriasis. Healthcare professionals are adopting targeted treatments, immune-modulators, and sophisticated biologics as a result of this expanding patient base. To meet these patients' unmet requirements, pharmaceutical companies are increasing their research and development expenditures. Treatment adoption rates are also increased by favourable healthcare regulations and improved access to dermatological care. All things considered, the growing prevalence of autoimmune skin conditions drives steady market expansion.

Restraint:

High cost of biologic and advanced therapies

The inability of many patients to pay for these medicines restricts their access and adherence. High costs also put a strain on insurance companies and healthcare systems. This results in limited coverage and difficulties with reimbursement. Patients might choose less effective options as a result. These monetary obstacles hinder the uptake of cutting-edge treatments and limit market growth.

Opportunity:

Growth in healthcare expenditure and diagnostics

Patient outcomes are improved by increased funding, which encourages the use of cutting-edge biologics and focused treatments. More precise disease classification and earlier detection are made possible by advancements in diagnostic capabilities. Timely intervention by early and accurate diagnosis slows the progression and complications of disease. Increased access to treatment in both urban and rural areas is made possible by growing healthcare infrastructure. These elements work together to increase demand and grow the market for treatments for autoimmune skin conditions.

Threat:

Safety concerns and adverse effects

The danger of serious side effects, like infections or organ damage, is present with many treatments. These health hazards may cause patients to avoid or stop receiving therapy. Additionally, doctors can be reluctant to recommend particular medications if their safety profiles are weak. Patient compliance and market acceptance are lowered as a result. Therefore, the adoption of beneficial medicines is slowed by the fear of danger.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Autoimmune Skin Diseases Treatment Market by disrupting supply chains, delaying clinical trials, and limiting patient access to healthcare facilities. Lockdowns and healthcare resource reallocation led to postponed diagnoses and treatment schedules, impacting patient outcomes. Telemedicine adoption accelerated, enabling remote consultations and prescription management. Pharmaceutical companies faced challenges in production and distribution but also saw increased focus on developing advanced therapies. Post-pandemic recovery is driven by resumed elective treatments, improved healthcare accessibility, and growing awareness of autoimmune skin disease management.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period by offering targeted therapies that address the underlying immune system dysfunction. These treatments provide higher efficacy and longer remission periods compared to conventional drugs, boosting patient demand. Advancements in biologic formulations and delivery methods enhance safety and convenience, increasing adoption rates. Growing approvals of novel biologics for conditions like psoriasis and atopic dermatitis expand the treatment portfolio. Rising awareness among healthcare providers and patients further accelerates market growth for biologics.

The homecare settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare settings segment is predicted to witness the highest growth rate by offering patients convenient access to therapies and monitoring in their own homes, reducing the need for frequent hospital visits. It supports better treatment adherence through self-administration options and remote guidance from healthcare providers. Advancements in portable devices and telemedicine enhance the feasibility of home-based care. Overall, homecare settings improve patient outcomes while lowering healthcare costs, driving market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share is driven by high disease prevalence, well developed healthcare infrastructure, and robust research funding. Advanced pharmaceuticals particularly biologics and JAK inhibitors plus favourable reimbursement policies support rapid adoption of novel therapies. Regulatory agencies facilitate accelerated drug approvals and bio similar entry. Cutting edge diagnostic and precision medicine technologies, including AI assisted imaging and multiplex assays, are increasingly used, with strategic collaborations between biotech firms and academic institutions powering continuous innovation in therapies for conditions such as psoriasis, eczema and lupus.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR is fuelled by rising autoimmune disease incidence tied to aging populations, urbanization and evolving lifestyles. Investments in healthcare infrastructure, expansion of public insurance coverage and generics production bolster treatment access. Emerging technologies include AI enabled teledermatology, mobile diagnostics, and hyper spectral imaging and nanostructure topical therapeutics under development. Regional innovation trends emphasize cost-effective, localized solutions-often in collaboration with global pharma supporting scalable deployment of diagnostics and precision therapies tailored to regional needs and healthcare disparities.

Key players in the market

Some of the key players in Autoimmune Skin Diseases Treatment Market include AbbVie Inc., Amgen Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, Biogen Inc., Sanofi S.A., UCB S.A., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., AstraZeneca plc, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Horizon Therapeutics plc and Incyte Corporation.

Key Developments:

In April 2025, Amgen announced a $900 million expansion of its New Albany, Ohio biomanufacturing facility. The investment aims to boost production capacity for both pipeline and commercial biologics, potentially supporting treatments in autoimmune dermatology. This expansion strengthens Amgen's manufacturing network to meet growing global demand for innovative therapies.

In January 2025, AbbVie completed its ~$200 million acquisition of Nimble Therapeutics, gaining its lead oral peptide IL 23 receptor inhibitor for psoriasis and inflammatory bowel disease, along with Nimble's proprietary peptide drug discovery platform to advance targeted autoimmune disease therapies.

In June 2023, Eli Lilly agreed to acquire Dice Therapeutics for $2.4 billion in cash (approximately $48 per share). The deal focuses on Dice's innovative oral IL 17 inhibitors, notably DC 806 in phase II psoriasis trials, along with other pipeline assets aimed at advancing treatments for autoimmune and inflammatory skin diseases.

Disease Types Covered:

Psoriasis
Atopic Dermatitis
Vitiligo
Pemphigus Vulgaris
Lupus Erythematosus
Other Disease Types

Therapy Types Covered:

Biologics
Corticosteroids
Immunosuppressants
Small Molecule Drugs
Other Therapy Types

Route of Administrations Covered:

Oral
Injectable
Topical

End Users Covered:

Hospitals
Specialty Clinics
Homecare Settings
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Autoimmune Skin Diseases Treatment Market, By Disease Type

5.1 Introduction
5.2 Psoriasis
5.3 Atopic Dermatitis
5.4 Vitiligo
5.5 Pemphigus Vulgaris
5.6 Lupus Erythematosus
5.7 Other Disease Types

6 Global Autoimmune Skin Diseases Treatment Market, By Therapy Type

6.1 Introduction
6.2 Biologics
6.3 Corticosteroids
6.4 Immunosuppressants
6.5 Small Molecule Drugs
6.6 Other Therapy Types

7 Global Autoimmune Skin Diseases Treatment Market, By Route of Administration

7.1 Introduction
7.2 Oral
7.3 Injectable
7.4 Topical

8 Global Autoimmune Skin Diseases Treatment Market, By End User

8.1 Introduction
8.2 Hospitals
8.3 Specialty Clinics
8.4 Homecare Settings
8.5 Other End Users

9 Global Autoimmune Skin Diseases Treatment Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 AbbVie Inc.
11.2 Amgen Inc.
11.3 Eli Lilly and Company
11.4 Johnson & Johnson Services, Inc.
11.5 Novartis AG
11.6 Pfizer Inc.
11.7 Bristol Myers Squibb Company
11.8 Biogen Inc.
11.9 Sanofi S.A.
11.10 UCB S.A.
11.11 GlaxoSmithKline plc
11.12 Regeneron Pharmaceuticals, Inc.
11.13 AstraZeneca plc
11.14 Merck & Co., Inc.
11.15 Takeda Pharmaceutical Company Limited
11.16 Roche Holding AG
11.17 Horizon Therapeutics plc
11.18 Incyte Corporation

自己免疫性皮膚疾患治療市場の2032年までの予測： 疾患タイプ別、治療タイプ別、投与経路別、エンドユーザー別、地域別の世界分析

Autoimmune Skin Diseases Treatment Market Forecasts to 2032 - Global Analysis By Disease Type, Therapy Type, Route of Administration, End User and By Geography

COVID-19の影響

最大のシェアを占める地域

CAGRが最も高い地域

無料カスタマイズサービス

本レポートをご購読の顧客は、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の自己免疫性皮膚疾患治療市場：疾患タイプ別

第6章 世界の自己免疫性皮膚疾患治療市場：治療タイプ別

第7章 世界の自己免疫性皮膚疾患治療市場：投与経路別

第8章 世界の自己免疫性皮膚疾患治療市場：エンドユーザー別

第9章 世界の自己免疫性皮膚疾患治療市場：地域別

第10章 主要開発

第11章 企業プロファイリング